NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for NCEL. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: NCEL is a Sell candidate.
NCEL stock price ended at $2.35 on 星期三, after rising 10.85%
On the latest trading day Apr 01, 2026, the stock price of NCEL rose by 10.85%, climbing from $2.31 to $2.35. Throughout the session, the stock experienced a volatility of 9.78%, with prices fluctuating between a daily low of $2.25 and a high of $2.47. Alongside this price increase, trading volume also rose by 8.6K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 32.0K shares were traded, amounting to a market value of approximately $10.7M.